35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience

Abstract Frontline high-dose therapy (HDT) is, in 2025, the standard of care for patients with multiple myeloma (MM) who are eligible for autologous stem cell transplantation (ASCT). Prior to high-dose melphalan, induction therapy with quadruplet combinations is also proposed systematically when pos...

وصف كامل

محفوظ في:
التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Philippe Moreau, Cyrille Hulin, Alexis Talbot, Hélène Demarquette, Léo Caillot, Thomas Chalopin, Arthur Bobin, Salomon Manier, Xavier Leleu, Lionel Karlin, Denis Caillot, Cécile Sonntag, Pierre Feugier, Murielle Roussel, Romain Gounot, Margaret Macro, Mohamad Mohty, Laurent Garderet, Mourab Tiab, Frédérique Orsini-Piocelle, Laure Vincent, Nathalie Meuleman, Jean Fontan, Lidia Montes, Marie-Christiane Vekemans, Martine Escoffre-Barbe, Jean-Richard Eveillard, Jean-Marc Schiano de Colella, Jérôme Lambert, Jean-Yves Mary, Jean-Paul Fermand, Bertrand Arnulf, Jill Corre, Hervé Avet-Loiseau, Thierry Facon, Jean-Luc Harousseau, Cyrille Touzeau, Aurore Perrot
التنسيق: Artigo
اللغة:Inglês
منشور في: Nature Publishing Group 2025-10-01
سلاسل:Blood Cancer Journal
الوصول للمادة أونلاين:https://doi.org/10.1038/s41408-025-01387-6
الوسوم: إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة